An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Completed · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.

Key facts

Study ID

NCT03029780

Run by

Bristol-Myers Squibb

People needed

104

Starts

2017-02-16

Expected to finish

2021-06-15

Last updated by the study team

2022-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Renal Cell Carcinoma
• Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
• Must have at least 1 lesion with measurable disease

You may not qualify if…

• Subjects with active central nervous system metastases
• Subjects who received prior therapy with checkpoint inhibitor
• Subjects with active, known or suspected autoimmune disease
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Cancer Specialists of North FL — Jacksonville, Florida, United States
• University Of Iowa Hospitals And Clinics — Iowa City, Iowa, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• Local Institution — Pittsburgh, Pennsylvania, United States
• Local Institution — Waratah, New South Wales, Australia
• Local Institution — Westmead, New South Wales, Australia
• Local Institution — Herston, Queensland, Australia
• Local Institution — Elizabeth Vale, South Australia, Australia
• Local Institution — Malvern, Victoria, Australia
• Centro Internacional de Estudios Clinicos — Recoleta, Santiago de Chile, Chile
• Fundacion Arturo Lopez Perez — Santiago, Santiago Metropolitan, Chile

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.